Medicare AdvantageSeptember 13, 2023
Clinical Criteria updates - June 2023
On August 19, 2022, September 12, 2022, November 18, 2022, February 24, 2023, May 19, 2023, June 12, 2023, and July 11, 2023, the Pharmacy and Therapeutic (P&T) Committee approved the following Clinical Criteria applicable to the medical drug benefit for Anthem Blue Cross and Blue Shield (Anthem). These policies were developed, revised, or reviewed to support clinical coding edits.
Visit Clinical Criteria to search for specific policies. If you have questions or would like additional information, use this email.
Please see the explanation/definition for each category of Clinical Criteria below:
- New: newly published criteria
- Revised: addition or removal of medical necessity requirements, new document number
- Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive
Please share this notice with other providers in your practice and office staff.
Note:
- The Clinical Criteria listed below applies only to the medical drug benefits contained within the member’s medical policy. This does not apply to pharmacy services.
- This notice is meant to inform the provider of new or revised criteria that has been adopted by Anthem only. It does not include details regarding any authorization requirements. Authorization rules are communicated via a separate notice.
Effective date | Document number | Clinical Criteria title | New or revised |
October 18, 2023 | *CC-0243 | Vyjuvek (beremagene geperpavec) | New |
October 18, 2023 | *CC-0242 | Epkinly (epcoritamab-bysp) | New |
October 18, 2023 | *CC-0241 | Elfabrio (pegunigalsidase alfa-iwxj) | New |
October 18, 2023 | CC-0228 | Leqembi (lecanemab) | Revised |
October 18, 2023 | *CC-0061 | Gonadotropin Releasing Hormone Analogs for the Treatment of Non-Oncologic Indications | Revised |
October 18, 2023 | *CC-0015 | Infertility and HCG Agents | Revised |
October 18, 2023 | *CC-0062 | Tumor Necrosis Factor Antagonists | Revised |
October 18, 2023 | CC-0151 | Yescarta (axicabtagene ciloleucel) | Revised |
October 18, 2023 | *CC-0177 | Zilretta (triamcinolone acetonide extended-release) | Revised |
October 18, 2023 | CC-0149 | Select Clotting Agents for Bleeding Disorders | Revised |
October 18, 2023 | CC-0032 | Botulinum Toxin | Revised |
October 18, 2023 | *CC-0002 | Colony Stimulating Factor Agents | Revised |
October 18, 2023 | *CC-0001 | Erythropoiesis Stimulating Agents | Revised |
October 18, 2023 | *CC-0174 | Kesimpta (ofatumumab) | Revised |
October 18, 2023 | *CC-0209 | Leqvio (inclisiran) | Revised |
October 18, 2023 | *CC-0011 | Ocrevus (ocrelizumab) | Revised |
October 18, 2023 | *CC-0005 | Hyaluronan Injections - Medicare Only | Revised |
MULTI-BCBS-CR-036939-23-CPN36113
PUBLICATIONS: October 2023 Provider Newsletter
To view this article online:
Or scan this QR code with your phone